» Articles » PMID: 37113539

Clozapine Prescription Rates in Southeast Europe: A Cross-sectional Study

Overview
Specialty Psychiatry
Date 2023 Apr 28
PMID 37113539
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: International reports indicate that clozapine is under prescribed. Yet, this has not been explored in Southeast European (SEE) countries. This cross-sectional study investigates clozapine prescription rates in a sample of 401 outpatients with psychosis from Bosnia and Herzegovina, Kosovo by United Nations resolution, North Macedonia, Montenegro and Serbia.

Methods: Descriptive analysis was used to explore clozapine prescription rates; daily antipsychotic dosage was calculated and converted into olanzapine equivalents. Patients receiving clozapine were compared to those not receiving clozapine; next those that were on clozapine monotherapy were compared to those who were on clozapine polytherapy regime.

Results: It was showed that clozapine was prescribed to 37.7% of patients (with cross-country variation: from 25% in North Macedonia to 43.8% in Montenegro), with average dose of 130.7 mg/daily. The majority of patients on clozapine (70.5%) were prescribed at least one more antipsychotic (the most frequent combination was with haloperidol).

Discussion: Our findings suggested that clozapine prescription rate in SEE outpatients is higher than in Western Europe. The average dose is significantly below the optimal therapeutic dosage recommended by clinical guidelines, and clozapine polytherapy is common. This might indicate that clozapine is prescribed mainly for its sedative effect rather than antipsychotic. We hope that this finding will be taken up by relevant stakeholders to address this non-evidence-based practice.

Citing Articles

Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia.

Vieira J, Reis E, Guerra Jr A, de Oliveira H, Ruas C Front Psychiatry. 2024; 15:1421501.

PMID: 38962057 PMC: 11220267. DOI: 10.3389/fpsyt.2024.1421501.


Clinical and pharmacological factors influencing serum clozapine and norclozapine levels.

Mach A, Wnorowska A, Siwek M, Wojnar M, Radziwon-Zaleska M Front Pharmacol. 2024; 15:1356813.

PMID: 38601469 PMC: 11004283. DOI: 10.3389/fphar.2024.1356813.

References
1.
Cohen D . Prescribers fear as a major side-effect of clozapine. Acta Psychiatr Scand. 2014; 130(2):154-5. DOI: 10.1111/acps.12294. View

2.
Divac N, Maric N, Damjanovic A, Jovanovic A, Jasovic-Gasic M, Prostran M . Use or underuse of therapeutic guidelines in psychiatry?. Psychiatr Danub. 2009; 21(2):224-9. View

3.
Grover S, Hazari N, Kate N, Chakraborty K, Sharma A, Singh D . Management of tardive syndromes with clozapine: a case series. Asian J Psychiatr. 2014; 8:111-4. DOI: 10.1016/j.ajp.2013.12.016. View

4.
Ignjatovic Ristic D, Cohen D, Obradovic A, Nikic-duricic K, Draskovic M, Hinic D . The Glasgow antipsychotic side-effects scale for clozapine in inpatients and outpatients with schizophrenia or schizoaffective disorder. Nord J Psychiatry. 2017; 72(2):124-129. DOI: 10.1080/08039488.2017.1400097. View

5.
Priebe S, Huxley P, Knight S, Evans S . Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999; 45(1):7-12. DOI: 10.1177/002076409904500102. View